OncoZenge AB (publ)

DB:8LY Stock Report

Market Cap: €3.6m

OncoZenge Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Stian Kildal

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.2yrs
CEO ownership2.3%
Management average tenureno data
Board average tenureless than a year

Recent management updates

Recent updates

CEO

Stian Kildal

1.2yrs

Tenure

Mr. Stian Kildal is Chief Executive Officer of OncoZenge AB (publ) from September 13, 2023.

Board Members

NamePositionTenureCompensationOwnership
Stephen T. Sonis
Member of Advisory Boardless than a yearno datano data
Christoph Nowak
Independent Directorless than a yearno datano data
Niclas Holmgren
Independent Director1.3yrsno datano data
Pooja Patel
Member of Advisory Boardless than a yearno datano data
Daniel Ehrenstrahle
Independent Chairman of the Boardless than a yearno datano data
Paolo Bossi
Member of the Advisory Boardless than a yearno datano data

0.9yrs

Average Tenure

38yo

Average Age

Experienced Board: 8LY's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.